Inbites Ecosystem Recruits Dr. Kim Hong-seok, Former Chong Kun Dang Scientist, as CTO

"Will Accelerate New Drug Development"

Invites Ecosystem announced on the 12th that it has recruited Kim Hong-seok, former head of research planning at Chong Kun Dang Hyojong Research Institute, as its Chief Technology Officer (CTO) and Vice President.

InVites Ecosystem CI.
[Image provided by CG InVites]

CTO Kim Hong-seok earned his Ph.D. in tumor genetics from the Department of Pathology at Catholic University Medical School in 2005. He conducted postdoctoral research on tumors at Columbia University College of Physicians and Surgeons and the National Cancer Institute of the U.S. National Institutes of Health. Notably, he has experience researching brain tumor-specific mutant genes using tumor stem cells in the Neuro-Oncology Branch, which conducts research for The Cancer Genome Atlas (TCGA).

CTO Kim was responsible for new drug research using stem cells at JW Pharmaceutical's New Drug Research Institute and worked on CRISPR/CAS9 gene-editing technology at ToolGen. At Macrogen, he was in charge of model animal production, NGS clinical laboratory, CES-Oligo business division, and stem cell research. Until recently, he served as head of research planning at Chong Kun Dang Hyojong Research Institute, managing and planning new drug research projects.

CTO Kim will oversee the entire research and development (R&D) at Invites Ecosystem, taking charge of discovering and advancing cancer vaccines and anticancer drug projects through genomic data. Invites Ecosystem emphasized that he will accelerate strengthening CG Invites' R&D capabilities and building a bio new drug pipeline.

An official from Invites Ecosystem stated, "With CTO Kim Hong-seok joining Invites Ecosystem, we will implement the full-cycle value chain of the bio-healthcare business pursued by the ecosystem by utilizing R&D fields conducted by each company. Through various areas, Invites Ecosystem is expected to leverage his diverse research experience and new drug development know-how to strengthen and expand new drug R&D using the bio platform, ultimately advancing as a specialized healthcare company."

Kim Hong-seok, Chief Technology Officer (CTO) of Inbites Ecosystem.
[Photo by CG Inbites]

This content was produced with the assistance of AI translation services.